1TVCC, CVSc. and AH, NDUAT, Kumarganj-224 229, Ayodhya, Uttar Pradesh, India
Department of Surgery and Radiology, College of Veterinary and Animal Sciences, Govind Ballabh Pant University of Agriculture and Technology, Pantnagar-263 145, Uttarakhand, India
*Corresponding Author: Deepti Bodh, Department of Surgery and Radiology, College of Veterinary and Animal Sciences, Govind Ballabh Pant University of Agriculture and Technology, Pantnagar-263 145, Uttarakhand, India, Email: deeptibodh@yahoo.in
Online published on 1 December, 2020.
The objective of present study was to investigate the efficacy of cultured allogenic bone marrow derived mesenchymal stem cell (BMMSCs) implant with insulin therapy for increasing osteosynthesis in bone gap defects in diabetic rabbits. Thirty six, clinically healthy New Zealand White rabbits were divided into four groups: A, B, C and D. Diabetes was induced experimentally in all rabbits, except group A. A 5 mm bone defect was created in right radii of all rabbits and following treatment was given: hydroxyapatite granules (group A and B), hydroxyapatite granules and insulin therapy (group C), cultured allogenic BMMSCs in hydroxyapatite scaffold and insulin therapy (group D). Clinical and radiographic parameters were recorded at days 0, 30, 60 and 90. It may be conducted that cultured allogenic bone marrow derived mesenchymal stem cells in hydroxyapatite scaffold along with local insulin therapy produces faster and better healing in alloxan-induced diabetic rabbits compared to healthy control, untreated diabetic and local insulin treated groups.
Alloxan monohydrate, Diabetes, Hydroxyapatite, Insulin, Mesenchymal stem cells, Rabbits
